Table 1. Nobiletin reverses the ABCB1-mediated drug resistance to 5-fluorouracil, docetaxel and doxorubicin in A2780/T cells.
| A2780/T | ||
|---|---|---|
| Drug | IC50 ± SD (μM) | fold reversal |
| Paclitaxel | 2.67 ± 0.22 | 1.00 |
| +0.5 μM N | 0.90 ± 0.15*** | 3.00 |
| +1.5 μM N | 0.15 ± 0.02*** | 18.47 |
| +4.5 μM N | 0.02 ± 0.004*** | 163.46 |
| +9 μM N | 0.006 ± 0.0002*** | 432.98 |
| Docetaxel | 17.9 ± 2.89 | 1.00 |
| +0.5 μM N | 8.97 ± 1.46* | 2.05 |
| +1.5 μM N | 3.57 ± 0.58** | 5.01 |
| +4.5 μM N | 1.13 ± 0.18*** | 15.84 |
| Doxorubicin | 5.97 ± 0.49 | 1.00 |
| +0.5 μM N | 3.77 ± 0.30** | 1.58 |
| +1.5 μM N | 1.89 ± 0.16*** | 3.16 |
| +4.5 μM N | 1.13 ± 0.18*** | 5.39 |
| +9 μM N | 0.38 ± 0.04*** | 15.92 |
| Daunorubicin | 11.91 ± 0.97 | 1.00 |
| +0.5 μM N | 9.46 ± 0.77 | 1.26 |
| +1.5 μM N | 4.49 ± 0.73* | 2.70 |
| +4.5 μM N | 0.89 ± 0.15** | 13.58 |
| 5-Fluorouracil | 159.19 ± 18.30 | 1.00 |
| +0.5 μM N | 132.2 ± 23.78 | 1.21 |
| +1.5 μM N | 79.78 ± 9.18* | 1.99 |
| +4.5 μM N | 26.14 ± 1.77* | 6.08 |
Cell growth was determined using the SRB assay. The data are representative of three different experiments and are shown as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, means significantly different from the control group in the absence of nobiletin.